Platform|API|Archive|Contact

Humanexa SignalsPharmaceutical Intelligence

FDA
EMA
MHRA
PMDA
Health Canada

Phase I
Phase II
Phase III
Readouts
Enrollment Signals

Pipeline Tracking
Company Moves
Asset Intelligence
Landscape Reports

Pricing
Access
Commercial
Launch Tracking

Licensing
Acquisitions
Partnerships
Capital Raises

Strategy Catalysts Pricing

Humanexa Signals

Data-driven pharmaceutical intelligence for biotech investors, pharma operators, consultants, and intelligence teams.

Powered by Humanexa

Categories

Regulatory
Clinical
Competitive
Markets
M&A Watch
Strategy
Catalyst Tracker

Company

Pricing
Partner with us
Subscribe
Contact
Privacy

Subscribe to Humanexa Signals

Weekly intelligence for pharma decision-makers.

No paywall. No spam. Unsubscribe anytime.

© 2026 Humanexa Signals. All rights reserved.

Intelligence powered by the Humanexa engine.

Company

PD-L1

Pharmaceutical intelligence for PD-L1 with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Assets: 2

Recent signals(2)

ClinicalJuly 26, 2026

Compound Kushen Injection Inhibits Immune Evasion in Hepatocellular Carcinoma via PD-L1 O-GlcNAcylation

Compound Kushen Injection (CKI) inhibits glycolysis and immune evasion in HCC cells by reducing O-GlcNAcylation of PD-L1.

ClinicalJuly 19, 2026

Galectin-3+PD-L1+ CECs identified as immunosuppressive drivers in TNBC

The study identifies Galectin-3+PD-L1+ CD71+ erythroid cells as key immunosuppressive components in triple-negative breast cancer.

Upcoming catalysts

No catalysts indexed for this entity yet.

Regulatory activity

No signals indexed for this entity yet.

Clinical activity(2)

ClinicalJuly 26, 2026

Compound Kushen Injection Inhibits Immune Evasion in Hepatocellular Carcinoma via PD-L1 O-GlcNAcylation

Compound Kushen Injection (CKI) inhibits glycolysis and immune evasion in HCC cells by reducing O-GlcNAcylation of PD-L1.

ClinicalJuly 19, 2026

Galectin-3+PD-L1+ CECs identified as immunosuppressive drivers in TNBC

The study identifies Galectin-3+PD-L1+ CD71+ erythroid cells as key immunosuppressive components in triple-negative breast cancer.

Competitive activity

No signals indexed for this entity yet.

Assets

Therapeutic areas

Breast Cancer →

Hepatocellular Carcinoma →

Indications

Breast Cancer →

Hepatocellular Carcinoma →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.